Is Mirum Pharmaceuticals, Inc. (MIRM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.1% / 30% | 7.4% / 30% | 2.4% / 30% | 2.44% / 5% | ✓ HALAL |
| DJIM | 6.1% / 33% | 7.4% / 33% | 2.4% / 33% | 2.44% / 5% | ✓ HALAL |
| MSCI | 37.9% / 33% | 45.5% / 33% | 14.6% / 33% | 2.44% / 5% | ✗ NOT HALAL |
| S&P | 6.1% / 33% | 7.4% / 33% | 2.4% / 33% | 2.44% / 5% | ✓ HALAL |
| FTSE | 37.9% / 33% | 45.5% / 33% | 14.6% / 50% | 2.44% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 80.8% | |
| Operating Margin | -3.1% | |
| Net Margin | -4.5% | |
| Return on Equity (ROE) | -8.6% | |
| Return on Assets (ROA) | -1.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $56M |
| Free Cash Flow | $55M |
| Total Debt | $319M |
| Debt-to-Equity | 101.5 |
| Current Ratio | 2.7 |
| Total Assets | $843M |
Price & Trading
| Last Close | $88.88 |
| 50-Day MA | $96.15 |
| 200-Day MA | $74.37 |
| Avg Volume | 806K |
| Beta | 0.5 |
|
52-Week Range
$36.88
| |
About Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Purification Calculator
As a halal stock with 2.44% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Mirum Pharmaceuticals, Inc. (MIRM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Mirum Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Mirum Pharmaceuticals, Inc.'s debt ratio?
Mirum Pharmaceuticals, Inc.'s debt ratio is 6.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 37.9%.
Does Mirum Pharmaceuticals, Inc. require dividend purification?
Yes, Mirum Pharmaceuticals, Inc. has an impermissible income ratio of 2.44%, which means 2.44% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Mirum Pharmaceuticals, Inc.'s key financial metrics?
Mirum Pharmaceuticals, Inc. has a market capitalization of $5.3B, and revenue of $521M. The company maintains a gross margin of 80.8% and a net margin of -4.5%. Return on equity stands at -8.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.